families (Families 1, 3, 4, and 5) shared FAF-relevant haplotypes, which strongly indicated the presence of a founder effect in Japanese FAF. This interpretation was also in accordance with the findings of previous studies conducted on two Japanese FAF families [29]. In Family 2 where there are no other affected family members, there is only a 196-kb segment of the shared haplotype at most, which spans two haploblocks. These observations suggest that presence of the founder haplotype is less likely in Family 2. II-1 is the only affected individual in Family 2, and the parents of II-1 died in their 80s and 90s without any symptoms suggesting FAF. To evaluate the penetrance associated with the p.Asp187Asn mutation, we analyzed the cumulative age at onset of the initial clinical symptoms in all the individuals described in the literature (n=38) [4, 8, 10–19, 22, 24, 31, 32–36] or in this study (n=6). As shown in Fig. 3b, 72.7 % of the patients develop symptoms by 50s, 95.4 % by 60s, and all the patients by 70s, which indicates that the p.Asp187Asn mutation is completely penetrant by 70s. Thus, the parents of II-1 in Family 2 are unlikely to carry the mutation considering the ages of the parents and the high penetrance associated with the p.Asp187Asn mutation. Taken together with the observation that only a very small segment of the founder haplotype was observed in Family 2, these observations strongly support the possibility of a de novo mutation event in Family 2. In accordance with this interpretation, the mutation involves the CpG sequence, a mutation hot spot. The possibility of a de novo mutation, however, could not be confirmed because the parents were unavailable for the analysis.

In conclusion, the present study demonstrated that the clinical presentations of patients with FAF are considerably broad despite the finding that all the patients carry the same c.654G>A (p.Asp187Asn) mutation. Detailed haplotype analyses demonstrated a founder mutation in most of the Japanese families with FAF, except for a sporadic patient in whom a *de novo* mutation event is suggested as the origin of the mutation.

Acknowledgments We thank the patients and the family members for their participation in this study. This work was supported in part by KAKENHİ (Grant-in-Aid for Scientific Research on Innovative Areas), Global COE Program, Integrated Database Project, and Scientific Research (A) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and a Grant-in-Aid for Research on Intractable Diseases and Comprehensive Research on Disability Health and Welfare from the Ministry of Health, Welfare and Labour, Japan.

## References

Meretoja J (1969) Familial systemic amyloidosis with lattice dystrophy of the cornea, progressive cranial neuropathy, skin changes and various internal symptoms. A previously unrecognized heritable syndrome. Ann Clin Res 1(4):314

–324

- Chastan N, Baert-Desurmont S, Saugier-Veber P, Dérumeaux G, Cabot A, Frébourg T, Hannequin D (2006) Cardiac conduction alterations in a French family with amyloidosis of the Finnish type with the p.Asp187Tyr mutation in the gene. Muscle Nerve 33(1):113–119
- Maury CPJ, Kere J, Tolvanen R, de la Chapelle A (1990) Finnish hereditary amyloidosis is caused by a single nucleotide substitution in the gelsolin gene. FEBS Lett 276(1–2):75–77
- de la Chapelle A, Kere J, Sack GH Jr, Tolvanen R, Maury CPJ (1992) Familial amyloidosis, Finnish type: G654→A mutation of the gelsolin gene in Finnish families and an unrelated American family. Genomics 13:898–901
- de la Chapelle A, Tolvanen R, Boysen G, Santavy J, Bleeker-Wagemakers L, Maury CPJ, Kere J (1992) Gelsolin derived familial amyloidosis caused by asparagine or tyrosine substitution for aspartic acid at residue 187. Nat Genet 2:157–160
- Haltia M, Ghiso J, Prelli F, Gallo G, Kiuru S, Somer H, Palo J, Frangione B (1990) Amyloid in familial amyloidosis, Finnish type, is antigenically and structurally related to gelsolin. Am J Pathol 136:1223–1228
- Levy E, Haltia M, Fernandez-Madrid I, Koivunen O, Ghiso J, Prelli F, Frangione B (1990) Mutation in gelsolin gene in Finnish hereditary amyloidosis. J Exp Med 172:1865–1867
- Hiltunen T, Kiuru S, Hongell V, Heliö T, Palo J, Peltonen L (1991)
   Finnish type of familial amyloidosis: cosegregation of Asp<sub>187</sub>→
   Asn mutation of gelsolin with the disease in three large families.

   Am J Hum Genet 49:522–528
- Paunio T, Kiuru S, Hongell V, Mustonen E, Syvänen AC, Bengström M, Palo J, Peltonen L (1992) Solid-phase minisequencing test reveals Asp187→Asn (G654→A) mutation of gelsolin in all affected individuals with Finnish type of familial amyloidosis. Genomics 13:237–239
- Akiya S, Nishio Y, Ibi K, Uozumi H, Takahashi H, Hamada T, Onishi A, Ishiguchi H, Hoshii Y, Nakazato M (1996) Lattice corneal dystrophy type II associated with familial amyloid polyneuropathy type IV. Ophthalmology 103:1106–1110
- Ikeda M, Mizushima K, Fujita Y, Watanabe M, Sasaki A, Makioka K, Enoki M, Nakamura M, Otani T, Takatama M, Okamoto K (2007) Familial amyloid polyneuropathy (Finnish type) in a Japanese family: clinical features and immunocytochemical studies. J Neurol Sci 252:4–8
- Makishita H, Ikeda S, Yazaki M, Yamane M, Yumoto K, Maury CPJ, Yanagisawa N (1996) Post mortem pathological findings in a Japanese patient with familial amyloidosis, Finnish type (FAF) amyloid: Int J Exp Clin Invest 3:134-139
- Makishita H, Yazaki M, Matsuda M, Ikeda S, Yanagisawa N (1994) Familial amyloid polyneuropathy type IV (Finnish-type). A clinicopathological study. Rinsho Shinkeigaku 34:431–437
- 14. Makioka K, Ikeda M, Ikeda Y, Nakasone A, Osawa T, Sasaki A, Otani T, Arai M, Okamoto K (2010) Familial amyloid polyneur-opathy (Finnish type) presenting multiple cranial nerve deficits with carpal tunnel syndrome and orthostatic hypotension. Neurol Res 32:472-5
- Sunada Y, Shimizu T, Nakase H, Ohta S, Asaoka T, Amano S, Sawa M, Kagawa Y, Kanazawa I, Mannen T (1993) Inherited amyloid polyneuropathy type IV(gelsolin variant) in a Japanese family. Ann Neurol 33:57–62
- Sekine H, Obata H, Shirao S, Kusunoki S, Tsuru T (2004) A case of familial amyloid polyneuropathy type IV (Finnish type) with lattice corneal dystrophy type II. Rinsho Ganka (Jpn J Clin Ophthalmol) 58(2):217–222
- Asahina A, Yokoyama T, Ueda M, Ando Y, Ohshima N, Saito I, Tadokoro E, Hasegawa K (2011) Hereditary gelsolin amyloidosis: a new Japanese case with cutis laxa as a diagnostic clue. Acta Derm Venereol 91(2):201–3
- Gorevic PD, Munoz PC, Gorgeone G, Purcell JJ Jr, Rodriges M, Ghiso J, Levy E, Haltia M, Frangione B (1991) Amyloidosis due

- to a mutation of the gelsolin gene in an American family with lattice corneal dystrophy type II. NEJM 325:25.1780-1785
- Steiner RD, Paunio T, Uemichi T, Evans JP, Benson MD (1995) Asp187Asn mutation of gelsolin in an American kindred with familial amyloidosis, Finnish type (FAP IV). Hum Genet 95:327-330
- Huerva V, Velasco A, Sánchez MC, Mateo AJ, Matías-Guiu X. Lattice corneal dystrophy type II: clinical, pathologic, and molecular study in a Spanish family. Eur J Ophthalmol 17(3):424-9
- Donders PC, Blanksma LJ (1979) Meretoja syndrome. Lattice dystrophy of the comea with hereditary generalized amyloidosis. Ophthalmologica 178(3):173–80
- 22. Conceição I, Sales-Luis ML, De Carvalho M, Evangelista T, Fernandes R, Paunio T, Kangas H, Coutinho P, Neves C, Saraiva MJ (2003) Gelsolin-related familial amyloidosis, Finnish type, Portuguese family: clinical and neurophysiological studies. Muscle Nerve 28:715–721
- Stewart HS, Parveen R, Ridgway AE, Bonshek R, Black GC (2000) Late onset lattice corneal dystrophy with systemic familial amyloidosis, amyloidosis V, in an English family. Br J Ophthalmol 84(4):390–4
- Ardalan MR, Shoja MM, Kiuru-Enari S (2007) Amyloidosisrelated nephrotic syndrome due to a G654A gelsolin mutation: the first report from the Middle East. Nephrol Dial Transplant 22 (1):272-5
- Shokouhi G, Khosroshahi HT (2008) Ardalan–Shoja–Kiuru syndrome—hereditary gelsolin amyloidosis plus retinitis pigmentosa. Nephrol Dial Transplant 23(3):1071
- Hellena PS, Marcello PV, Emilia A, Rubens BJ, Miguel NB Jr (2011) Danish type gelsolin-related amyloidosis in a Brazilian family: case reports. Arq Bras Opthalmol 74(4):286–8
- Meretoja J (1973) Genetic aspects of familial amyloidosis with corneal lattice dystrophy and cranial neuropathy. Clin Genet 4:173–185

- 28. Kiuru-Enari S, Haltia M (2010) Hereditary gelsolin amyloidosis—40 years of Meretoja disease. Duodecim 126(10):1162–71
- Paunio T, Sunada Y, Kiuru S, Makishita H, Ikeda S, Weissenbach J, Palo J, Peltonen L (1995) Haplotype analysis in gelsolin-related amyloidosis reveals independent origin of identical mutation (G654A) of gelsolin in Finland and Japan. Hum Mutat 6:60–65
- 30. Miyazawa H, Kato M, Awata T, Kohda M, Iwasa H, Koyama N, Tanaka T, Huqun KS, Okazaki Y, Hagiwara K (2007) Homozygosity haplotype allows a genomewide search for the autosomal segment shared among patients. Am J Hum Genet 80:1090–1102
- Kiuru S (1998) Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid: Int J Exp Clin Invest 5:55–66
- Ghiso J, Haltia M, Prelli F, Novello J, Frangione B (1990) Gelsolin variant (Asn-187) in familial amyloidosis, Finnish type. Biochem J 272:827–830
- Maury CPJ, Kere J, Tolvanen R, de la Chapelle A (1992) Homozygosity for the Asn 187 gelsolin mutation in Finnish-type familial amyloidosis is associated with severe renal disease. Genomics 13:902–903
- 34. Maury CPJ, Liljeström M, Boysen G, Törnrorh T, de la Chapelle A, Nurmiaho-Lassila Eeva-liisa (2000) Danish type gelsolin related amyloidosis:654G-T mutation is associated with a disease pathogenetically and clinically similar to that caused by the 654G-A mutation (familial amyloidosis of the Finnish type). J Clin Pathol 53:95–99
- Tanskanen M, Paetau A, Salonen O, Salmi T, Lamminen A, Lindsberg P, Somer H, Kiuru-Enari S (2007) Severe ataxia with neuropathy in hereditary gelsolin amyloidosis: a case report. Amyloid 14(1):89-91
- Lüttmann RJ, Teismann I, Husstedt IW, Ringelstein EB, Kuhlenbäumer G (2010) Hereditary amyloidosis of the Finnish type in a German family: clinical and electrophysiological presentation. Muscle Nerve 41:679–684



